About PerkinElmer (NYSE:PKI)
PerkinElmer, Inc. is a provider of products, services and solutions to the diagnostics, research, environmental, industrial and laboratory services markets. The Company operates through two segments: Discovery & Analytical Solutions and Diagnostics. The Discovery & Analytical Solutions segment serves the environmental, food, industrial, life sciences research and laboratory services markets. It provides analytical instrumentation for the industrial market, which includes the chemical, electronics, energy, lubricant, petrochemical and polymer industries. Its products include AAnalyst, Altus, Aquamatic, Avio, AxION, Clarus, DairyGuard, AlphaLISA, AlphaPlex, AlphaScreen, Alpha SureFire, Cell carrier and cell::explorer. The Diagnostics segment is focused on reproductive health, emerging market diagnostics and applied genomics. Its products include AutoDELFIA, BACS-on-Beads, Bioo Scientific, BoBs, Datalytix, Dexela, Dexela CMOS FPDs, Evolution, ViaCord, and Zephyr.
Industry, Sector and Symbol:
- Sector: Computer and Technology
- Industry: Advanced Medical Equipment & Technology
- Sub-Industry: Life Sciences Tools & Services
- Symbol: NYSE:PKI
- CUSIP: 71404610
- Web: www.perkinelmer.com
- Market Cap: $7.90572 billion
- Outstanding Shares: 110,214,000
- 50 Day Moving Avg: $69.39
- 200 Day Moving Avg: $65.31
- 52 Week Range: $45.35 - $72.11
Sales & Book Value:
- Trailing P/E Ratio: 21.63
- Foreward P/E Ratio: 21.74
- P/E Growth: 2.44
- Annual Revenue: $2.14 billion
- Price / Sales: 3.69
- Book Value: $22.13 per share
- Price / Book: 3.24
- Annual Dividend: $0.28
- Dividend Yield: 0.4%
- EBITDA: $416.05 million
- Net Margins: 16.80%
- Return on Equity: 13.44%
- Return on Assets: 6.85%
- Debt-to-Equity Ratio: 0.45%
- Current Ratio: 2.43%
- Quick Ratio: 1.97%
- Average Volume: 624,871 shs.
- Beta: 0.72
- Short Ratio: 4.31
Frequently Asked Questions for PerkinElmer (NYSE:PKI)
What is PerkinElmer's stock symbol?
PerkinElmer trades on the New York Stock Exchange (NYSE) under the ticker symbol "PKI."
How often does PerkinElmer pay dividends? What is the dividend yield for PerkinElmer?
PerkinElmer announced a quarterly dividend on Monday, July 24th. Investors of record on Friday, October 20th will be given a dividend of $0.07 per share on Friday, November 10th. This represents a $0.28 annualized dividend and a yield of 0.39%. The ex-dividend date is Thursday, October 19th. View PerkinElmer's Dividend History.
How were PerkinElmer's earnings last quarter?
PerkinElmer, Inc. (NYSE:PKI) issued its quarterly earnings data on Thursday, August, 3rd. The company reported $0.67 EPS for the quarter, meeting the Zacks' consensus estimate of $0.67. The company earned $547 million during the quarter, compared to the consensus estimate of $554.14 million. PerkinElmer had a net margin of 16.80% and a return on equity of 13.44%. The company's revenue was up 2.0% on a year-over-year basis. During the same quarter in the prior year, the firm posted $0.67 earnings per share. View PerkinElmer's Earnings History.
When will PerkinElmer make its next earnings announcement?
What guidance has PerkinElmer issued on next quarter's earnings?
PerkinElmer issued an update on its FY17 earnings guidance on Thursday, August, 3rd. The company provided EPS guidance of $2.84-2.92 for the period, compared to the Thomson Reuters consensus EPS estimate of $2.85.
Where is PerkinElmer's stock going? Where will PerkinElmer's stock price be in 2017?
15 brokerages have issued 12 month target prices for PerkinElmer's stock. Their predictions range from $48.00 to $81.00. On average, they anticipate PerkinElmer's stock price to reach $67.69 in the next twelve months. View Analyst Ratings for PerkinElmer.
What are analysts saying about PerkinElmer stock?
Here are some recent quotes from research analysts about PerkinElmer stock:
- 1. According to Zacks Investment Research, "PerkinElmer holds ground on a strong global foothold, courtesy of its impending acquisition of Germany-based EUROIMMUN and takeover of India-based Tulip Diagnostics. The company continues to offer a global diagnostics portfolio focused on reproductive health, infectious disease screening and genomics offerings for oncology and other molecular tests. With an enhanced focus on product innovation and expansion into emerging markets, PerkinElmer has considerable potential upside. PerkinElmer delivered a solid first quarter, beating the Zacks Consensus Estimate on both the counts. The quarter witnessed solid organic revenue growth across all the business segments. Furthermore, a positive guidance instills our confidence on the stock. On the flipside, despite having a solid portfolio, unfavorable foreign exchange is a primary concern for PerkinElmer. Furthermore, PerkinElmer’s share price movement in the past one year has been unsatisfactory." (8/1/2017)
- 2. Cantor Fitzgerald analysts commented, "Newborn screening in China continues to drive strong diagnostic growth, despite a slight decline in the Haoyuan nucleic acid testing. Diagnostic revenue in China was up more than 20% y/y in 1Q17. Despite a slight moderation in birth rates, uptake of the automated Genetic Screening Processor (GSP) has driven menu expansion. The company reports that 20-25% of the market is now screening for ~20 disorders, while the remaining 80% is screening for 2-4 disorders. India, the largest newborn screening opportunity with an estimated 26M annual births, continues to be relatively unpenetrated, but we do not anticipate a steep adoption ramp as the company experienced in China. Increase in reported revenue guidance leaves organic growth unchanged. The company raised its 2017 revenue guidance to $2.200-2.220B from $2.19-2.20B, implying 4-5% y/y reported revenue growth, compared with our prior estimate of $2.199B. Notably, the 4% organic revenue growth rate is unchanged, and the company expects a slightly lower FX headwind for 2017." (5/5/2017)
Who are some of PerkinElmer's key competitors?
Some companies that are related to PerkinElmer include Waters (WAT), ResMed (RMD), Hologic (HOLX), Varian Medical Systems (VAR), ABIOMED (ABMD), Bruker Corporation (BRKR), Alere (ALR), Quidel Corporation (QDEL), Mazor Robotics (MZOR), Natus Medical Incorporated (BABY), Accelerate Diagnostics (AXDX), ABAXIS (ABAX), Luminex Corporation (LMNX), LeMaitre Vascular (LMAT), Pacific Biosciences of California (PACB), GenMark Diagnostics (GNMK), ViewRay (VRAY) and Accuray Incorporated (ARAY).
Who are PerkinElmer's key executives?
PerkinElmer's management team includes the folowing people:
- Robert F. Friel, Chairman of the Board, President, Chief Executive Officer
- Frank Anders Wilson CPA, Chief Financial Officer, Senior Vice President
- Deborah Butters, Chief Human Resource Officer, Senior Vice President
- James L. Corbett, Executive Vice President and President - Discovery & Analytical Solutions
- Joel S. Goldberg, Senior Vice President - Administration, General Counsel, Secretary
- Prahlad R. Singh, Senior Vice President and President - Diagnostics
- Daniel R. Tereau, Senior Vice President, Strategy and Business Development
- Andrew Okun, Chief Accounting Officer, Vice President
- Alexis P. Michas, Lead Independent Director
- Peter Barrett Ph.D., Independent Director
Who owns PerkinElmer stock?
PerkinElmer's stock is owned by a number of of retail and institutional investors. Top institutional investors include Fisher Asset Management LLC (0.52%), Assenagon Asset Management S.A. (0.30%), State Treasurer State of Michigan (0.03%), APG Asset Management N.V. (0.03%), Quantitative Systematic Strategies LLC (0.01%) and Mutual of America Capital Management LLC (0.01%). Company insiders that own PerkinElmer stock include Alexis P Michas, Andrew Okun, Daniel R Tereau, Frank Anders Wilson, James Corbett, Joel S Goldberg, Kenton J Sicchitano, Patrick J Sullivan, Peter Barrett, Prahlad R Singh, Robert F Friel and Vicki L Sato. View Institutional Ownership Trends for PerkinElmer.
Who sold PerkinElmer stock? Who is selling PerkinElmer stock?
PerkinElmer's stock was sold by a variety of institutional investors in the last quarter, including Fisher Asset Management LLC and State Treasurer State of Michigan. Company insiders that have sold PerkinElmer stock in the last year include Alexis P Michas, Andrew Okun, Daniel R Tereau, Joel S Goldberg, Patrick J Sullivan, Peter Barrett, Prahlad R Singh, Robert F Friel and Vicki L Sato. View Insider Buying and Selling for PerkinElmer.
Who bought PerkinElmer stock? Who is buying PerkinElmer stock?
PerkinElmer's stock was purchased by a variety of institutional investors in the last quarter, including Assenagon Asset Management S.A., APG Asset Management N.V., Quantitative Systematic Strategies LLC and Mutual of America Capital Management LLC. View Insider Buying and Selling for PerkinElmer.
How do I buy PerkinElmer stock?
Shares of PerkinElmer can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is PerkinElmer's stock price today?
MarketBeat Community Rating for PerkinElmer (NYSE PKI)MarketBeat's community ratings are surveys of what our community members think about PerkinElmer and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
One share of PerkinElmer stock can currently be purchased for approximately $71.73.
Consensus Ratings for PerkinElmer (NYSE:PKI) (How are Consensus Ratings Calculated?)
MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
|Ratings Breakdown: ||2 Sell Ratings, 8 Hold Ratings, 5 Buy Ratings|
|Consensus Rating:||Hold (Score: 2.20)|
|Consensus Price Target: ||$67.69 (5.63% downside)|Consensus Price Target History for PerkinElmer (NYSE:PKI)
Analysts' Ratings History for PerkinElmer (NYSE:PKI)
(Data available from 10/22/2015 forward)
|Date||Firm||Action||Rating||Price Target||Impact on Share Price||Details|
|10/20/2017||Jefferies Group LLC||Reiterated Rating||Hold||$70.00||N/A|
|10/20/2017||Robert W. Baird||Reiterated Rating||Buy||$72.00||N/A|
|10/6/2017||Morgan Stanley||Reiterated Rating||Overweight||$79.00 -> $77.00||N/A|
|9/26/2017||Goldman Sachs Group, Inc. (The)||Reiterated Rating||Neutral -> Neutral||$67.00||Low|
|9/26/2017||Citigroup Inc.||Reiterated Rating||Buy||$74.00 -> $80.00||Low|
|9/1/2017||Cowen and Company||Reiterated Rating||Hold||$70.00||Low|
|8/4/2017||Piper Jaffray Companies||Reiterated Rating||Buy||$81.00||Medium|
|7/16/2017||Cantor Fitzgerald||Reiterated Rating||Hold||Low|
|7/13/2017||Wells Fargo & Company||Initiated Coverage||Market Perform -> Market Perform||$72.00||Low|
|6/22/2017||Evercore ISI||Reiterated Rating||In-Line||$62.50 -> $68.00||Low|
|5/6/2017||Barclays PLC||Set Price Target||Sell||$55.00||Low|
|3/27/2017||Janney Montgomery Scott||Upgrade||Neutral -> Buy||Medium|
|2/5/2017||BTIG Research||Reiterated Rating||Hold||N/A|
|2/3/2017||Bank of America Corporation||Downgrade||Neutral -> Underperform||$48.00||N/A|
|1/18/2017||Deutsche Bank AG||Reiterated Rating||Hold||$55.00||N/A|
|8/5/2016||J P Morgan Chase & Co||Boost Price Target||Neutral||$52.00 -> $55.00||N/A|
|8/5/2016||Mizuho||Downgrade||Buy -> Neutral||$56.00||N/A|
|5/6/2016||Stifel Nicolaus||Boost Price Target||Buy||$51.00 -> $59.00||N/A|
|12/3/2015||Wedbush||Downgrade||Outperform -> Neutral||$56.00||N/A|
Earnings History for PerkinElmer (NYSE:PKI)Earnings History by Quarter for PerkinElmer (NYSE PKI)
(Data available from 1/1/2011 forward)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
|11/2/2017|| || || || || || || || |
|8/3/2017||Q2 2017||$0.67||$0.67||$554.14 million||$547.00 million||View||Listen|
|5/4/2017||Q1 2017||$0.54||$0.55||$506.81 million||$514.12 million||View||Listen|
|11/7/2016||Q3||$0.66||$0.68||$572.03 million||$548.00 million||View||Listen|
|5/5/2016||Q116||$0.51||$0.56||$532.55 million||$538.70 million||View||N/A|
|11/5/2015||Q315||$0.60||$0.60||$554.88 million||$563.00 million||View||N/A|
|7/30/2015||Q2||$0.59||$0.60||$555.66 million||$564.00 million||View||Listen|
|4/30/2015||Q115||$0.46||$0.50||$537.27 million||$526.90 million||View||N/A|
|1/29/2015||Q414||$0.78||$0.85||$602.35 million||$608.60 million||View||N/A|
|10/30/2014||Q3||$0.57||$0.67||$550.40 million||$542.05 million||View||Listen|
|8/7/2014||Q2||$0.59||$0.59||$572.26 million||$556.20 million||View||Listen|
|4/24/2014||Q114||$0.44||$0.46||$531.31 million||$531.90 million||View||Listen|
|1/30/2014||Q413||$0.70||$0.73||$588.95 million||$594.00 million||View||Listen|
|10/30/2013||Q313||$0.48||$0.49||$523.84 million||$524.30 million||View||Listen|
|8/1/2013||Q2 2013||$0.48||$0.51||$532.95 million||$543.30 million||View||Listen|
|4/25/2013||Q1 2013||$0.48||$0.36||$532.25 million||$505.38 million||View||Listen|
|1/31/2013||Q4 2012||$0.65||$0.65||$577.94 million||$577.00 million||View||Listen|
Earnings Estimates for PerkinElmer (NYSE:PKI)
2017 EPS Consensus Estimate: $2.95
2018 EPS Consensus Estimate: $3.50
(Data provided by Zacks Investment Research)
|Quarter||Number of Estimates||Low Estimate||High Estimate||Average Estimate|
Current Dividend Information for PerkinElmer (NYSE:PKI)
|Dividend Growth:||0.00% (3 Year Average)|
|Payout Ratio:||8.46% (Trailing 12 Months of Earnings) |
9.69% (Based on This Year's Estimates)
8.48% (Based on Next Year's Estimates)
Dividend History by Quarter for PerkinElmer (NYSE PKI)
(Data available from 1/1/2013 forward)
|Announced||Period||Amount||Yield||Ex-Dividend Date||Record Date||Payable Date|
Insider Trading and Institutional Ownership History for PerkinElmer (NYSE:PKI)
Insider Ownership Percentage: 2.20%Insider Trades by Quarter for PerkinElmer (NYSE:PKI)
Institutional Ownership Percentage: 91.47%
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Details|
|6/19/2017||Andrew Okun||Insider||Sell||4,358||$65.00||$283,270.00|| |
|6/1/2017||Peter Barrett||Director||Sell||10,000||$63.22||$632,200.00|| |
|5/15/2017||Patrick J Sullivan||Director||Sell||6,628||$62.59||$414,846.52|| |
|5/4/2017||Robert F Friel||Insider||Sell||25,100||$60.00||$1,506,000.00|| |
|4/27/2017||Robert F Friel||Insider||Sell||124,837||$60.11||$7,503,952.07|| |
|3/20/2017||Andrew Okun||Insider||Sell||3,000||$57.27||$171,810.00|| |
|3/13/2017||Joel S Goldberg||Insider||Sell||30,710||$55.45||$1,702,869.50|| |
|2/21/2017||Alexis P. Michas||Director||Sell||8,308||$55.60||$461,924.80|| |
|2/15/2017||Prahlad R Singh||Insider||Sell||9,576||$55.00||$526,680.00|| |
|2/9/2017||Daniel R Tereau||Insider||Sell||5,001||$53.16||$265,853.16|| |
|2/9/2017||Vicki L Sato||Director||Sell||8,308||$54.01||$448,715.08|| |
|2/6/2017||Daniel R Tereau||Insider||Sell||4,069||$52.01||$211,628.69|| |
|12/1/2016||Alexis P. Michas||Director||Sell||15,000||$51.00||$765,000.00|| |
|9/22/2016||Joel S Goldberg||Insider||Sell||38,095||$55.00||$2,095,225.00|| |
|9/12/2016||Daniel R Tereau||Insider||Sell||18,866||$52.00||$981,032.00|| |
|8/24/2016||Kenton J Sicchitano||Director||Sell||15,189||$54.87||$833,420.43|| |
|8/17/2016||Patrick J Sullivan||Director||Sell||8,308||$54.74||$454,779.92|| |
|6/2/2016||Alexis P Michas||Director||Sell||1,953||$54.85||$107,122.05|| |
|5/24/2016||Robert F Friel||CEO||Sell||128,300||$55.01||$7,057,783.00|| |
|5/16/2016||Robert F Friel||CEO||Sell||109,000||$55.01||$5,996,090.00|| |
|5/11/2016||Robert F Friel||CEO||Sell||10,685||$55.01||$587,781.85|| |
|5/10/2016||Vicki L Sato||Director||Sell||12,586||$54.51||$686,062.86|| |
|5/6/2016||Robert F Friel||CEO||Sell||4,116||$55.00||$226,380.00|| |
|4/18/2016||Daniel R Tereau||Insider||Sell||2,158||$50.79||$109,604.82|| |
|3/21/2016||James Corbett||Insider||Sell||1,723||$48.74||$83,979.02|| |
|2/24/2016||Alexis P. Michas||Director||Sell||10,000||$47.56||$475,600.00|| |
|12/3/2015||Kenton J Sicchitano||Director||Sell||10,216||$51.05||$521,526.80|| |
|11/3/2015||Frank Anders Wilson||insider||Sell||16,380||$52.69||$863,062.20|| |
|10/23/2015||Andrew Okun||Insider||Sell||2,000||$50.00||$100,000.00|| |
|9/14/2015||James Corbett||Insider||Sell||3,000||$47.59||$142,770.00|| |
|9/3/2015||Kenton J. Sicchitano||Director||Sell||12,586||$47.88||$602,617.68|| |
|6/5/2015||Alexis P Michas||Director||Sell||20,000||$52.25||$1,045,000.00|| |
|6/3/2015||Frank Anders Wilson||Insider||Sell||16,380||$52.60||$861,588.00|| |
|3/27/2015||Joel S Goldberg||Insider||Sell||10,646||$51.00||$542,946.00|| |
|3/23/2015||Andrew Okun||Insider||Sell||2,000||$50.09||$100,180.00|| |
|3/20/2015||James Corbett||Insider||Sell||5,157||$50.23||$259,036.11|| |
|3/18/2015||Joel S Goldberg||Insider||Sell||9,000||$49.00||$441,000.00|| |
|3/6/2015||Patrick J Sullivan||Director||Sell||12,586||$46.90||$590,283.40|| |
|3/5/2015||Alexis P Michas||Director||Sell||8,892||$47.00||$417,924.00|| |
|3/5/2015||Joel S Goldberg||Insider||Sell||9,000||$47.00||$423,000.00|| |
|2/10/2015||Vicki L Sato||Director||Sell||24,000||$45.55||$1,093,200.00|| |
|2/9/2015||Andrew Okun||Insider||Sell||6,262||$45.82||$286,924.84|| |
|2/3/2015||Nicholas A Lopardo||Director||Sell||8,892||$46.30||$411,699.60|| |
|2/3/2015||Robert F Friel||CEO||Sell||60,709||$46.26||$2,808,398.34|| |
|2/2/2015||Robert F Friel||CEO||Sell||319,065||$46.02||$14,683,371.30|| |
|11/14/2014||James C Mullen||Director||Sell||8,892||$43.73||$388,847.16|| |
|11/13/2014||Patrick J Sullivan||Director||Sell||8,892||$43.46||$386,446.32|| |
|9/4/2014||Kenton J Sicchitano||Director||Sell||8,892||$44.98||$399,962.16|| |
|7/2/2014||Daniel R Marshak||SVP||Sell||12,000||$48.00||$576,000.00|| |
|6/26/2014||Daniel R Marshak||SVP||Sell||10,000||$46.60||$466,000.00|| |
|6/19/2014||James Corbett||Insider||Sell||57,126||$46.69||$2,667,212.94|| |
|6/9/2014||Maurice H Tenney||Insider||Sell||5,504||$47.26||$260,119.04|| |
|6/9/2014||Robert F Friel||CEO||Sell||124,858||$46.70||$5,830,868.60|| |
|6/5/2014||Alexis P Michas||Director||Sell||9,146||$46.30||$423,459.80|| |
|6/2/2014||Alexis P Michas||Director||Sell||5,854||$45.00||$263,430.00|| |
|6/2/2014||Joel S Goldberg||Insider||Sell||17,000||$45.11||$766,870.00|| |
|5/12/2014||Alexis Michas||Director||Sell||5,000||$44.40||$222,000.00|| |
|4/29/2014||Nicholas Lopardo||Director||Sell||12,951||$41.98||$543,682.98|| |
|4/7/2014||James Corbett||Insider||Sell||22,027||$45.11||$993,637.97|| |
|3/12/2014||Daniel Marshak||SVP||Sell||19,292||$45.29||$873,734.68|| |
|3/11/2014||John Letcher||SVP||Sell||41,000||$45.40||$1,861,400.00|| |
|3/7/2014||Andrew Okun||CAO||Sell||9,398||$46.35||$435,597.30|| |
|2/27/2014||Alexis Michas||Director||Sell||5,000||$45.25||$226,250.00|| |
|2/14/2014||Vicki Sato||Director||Sell||21,843||$43.97||$960,436.71|| |
|2/7/2014||James Mullen||Director||Sell||12,951||$43.73||$566,347.23|| |
|12/13/2013||Maurice Tenney||Insider||Sell||25,000||$38.91||$972,750.00|| |
|12/10/2013||Daniel Marshak||SVP||Sell||12,183||$39.59||$482,324.97|| |
|11/14/2013||Robert Friel||CEO||Sell||112,461||$37.14||$4,176,801.54|| |
|9/10/2013||Robert F Friel||CEO||Sell||141,000||$37.45||$5,280,450.00|| |
|9/6/2013||Andrew Okun||CAO||Sell||6,805||$36.86||$250,832.30|| |
|5/1/2013||Alexis P Michas||Director||Sell||6,440||$30.85||$198,674.00|| |
|4/30/2013||James C Mullen||Director||Sell||6,440||$30.31||$195,196.40|| |
|4/11/2013||Maurice H Tenney||Insider||Sell||9,500||$35.00||$332,500.00|| |
|9/13/2012||Robert F Friel||CEO||Sell||50,565||$29.00||$1,466,385.00|| |
|8/9/2012||Kenton J Sicchitano||Director||Sell||9,454||$27.93||$264,050.22|| |
Headline Trends for PerkinElmer (NYSE:PKI)
Latest Headlines for PerkinElmer (NYSE:PKI)
Loading headlines, please wait.
PerkinElmer (PKI) Chart for Sunday, October, 22, 2017